ABCL
NASDAQ
CA
AbCellera Biologics Inc. - Common Shares
$3.52
▲ +$0.01
(+0.28%)
Vol 3.5M
4
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$1.0B
ROE
-17.0%
Margin
-486.0%
D/E
0.00
Beta
0.78
52W
$2–$7
Wall Street Consensus
14 analysts · Apr 20263
Strong Buy
9
Buy
2
Hold
0
Sell
0
Strong Sell
85.7%
Buy Rating
Price Chart
Earnings
Beat rate: 50.0%
Next Report
May 06, 2026
EPS Estimate: $-0.19
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $-0.19 | — | — |
| Dec 2025 | $-0.18 | $-0.03 | +$0.15 |
| Sep 2025 | $-0.17 | $-0.19 | $-0.02 |
| Jun 2025 | $-0.17 | $-0.12 | +$0.05 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Revenue | — | $5.0M | $4.2M | $17.1M | $9.0M | $44.9M |
| Net Income | — | -$34.2M | -$45.6M | -$34.7M | -$57.1M | -$8.9M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -15.9% | -15.9% | -15.9% | -15.9% | -17.0% | -17.0% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -203.3% | -503.9% | -503.9% | -503.9% | -486.0% | -486.0% |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 11.07 | 11.07 | 11.07 | 11.07 | 10.10 | 10.10 |
Key Ratios
ROA (TTM)
-12.6%
P/S (TTM)
28.98
P/B
0.8
EPS (TTM)
$-0.58
CF/Share
$-0.34
Rev Growth 3Y
-57.5%
52W High
$6.52
52W Low
$1.89
$1.89
52-Week Range
$6.52
Financial Health
Free Cash Flow
-$44.6M
Net Debt
$14.7M
Cash
$128.5M
Total Debt
$143.2M
As of Dec 31, 2025
How does ABCL compare to Life Sciences Tools & Services peers?
Peer group: Small-cap Life Sciences Tools & Services ($300M+) · 25 companies
ABCL valuation vs Life Sciences Tools & Services peers
P/E ratio
—
▼
0%
below
peers
(32.5)
vs Peers
vs Industry
Fair value
P/S ratio
29.0
▲
659%
above
peers
(3.8)
vs Peers
vs Industry
Overvalued
P/B ratio
0.8
▼
78%
below
peers
(3.7)
vs Peers
vs Industry
Undervalued
Div yield
—
▼
0%
below
peers
(0.5%)
vs Peers
vs Industry
Low yield
ABCL profitability vs Life Sciences Tools & Services peers
ROE
-17.0%
▼
418%
below
peers
(-3.3%)
vs Peers
vs Industry
Weak
Net margin
-486.0%
▼
5076%
below
peers
(-9.4%)
vs Peers
vs Industry
Weak
Gross margin
—
▼
0%
below
peers
(48.0%)
vs Peers
vs Industry
Top tier
ROA
-12.6%
▼
383%
below
peers
(-2.6%)
vs Peers
vs Industry
Weak
ABCL financial health vs Life Sciences Tools & Services peers
D/E ratio
0.0
▼
100%
below
peers
(36.5)
vs Peers
vs Industry
Low debt
Current ratio
10.1
▲
199%
above
peers
(3.4)
vs Peers
vs Industry
Strong liquidity
Beta
0.8
▼
45%
below
peers
(1.4)
vs Peers
vs Industry
More volatile
ABCL fundamentals radar
ABCL
Peer median
Industry
ABCL profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
ABCL vs peers: key metrics
Insider Activity
NeutralBuys
0
Sells
0
THERMOPYLAE HOLDINGS, LTD.
Beneficial Owner of more than… · Feb 27
38000 shs
BOOTH ANDREW
Chief Financial Officer · Feb 27
42600 shs
THERMOPYLAE HOLDINGS, LTD.
Beneficial Owner of more than… · Feb 26
177457 shs
Last 90 days
Top Holders
Top 5: 19.62%Baker Bros. Advisors, LP
9.08%
$90.0M
Capital World Investors
4.41%
$43.7M
UBS AM, a distinct business…
2.60%
$25.8M
Two Sigma Investments, LP
1.92%
$19.0M
Two Sigma Advisers, LP
1.61%
$16.0M
As of Dec 31, 2025
Latest News
No related news yet